The Extraordinary General Meeting of BioGaia on 18 March resolved to distribute
the shares in the subsidiary Infant Bacterial Therapeutics AB (IBT) to BioGaia’s
shareholders. On 29 March 2016, trading of IBT’s class B shares commenced on
Nasdaq First North. IBT’s results up to March 29 will be consolidated in
BioGaia’s financial statements.
IBT has today announced a rights issue. The prospectus that IBT will make public
in relation to the rights issue will include IBT’s results for the first quarter
of 2016. The loss for the period was SEK -5.2 million, compared to SEK -3.7
million corresponding period of last year, and is included in BioGaia’s profit
for the first quarter. Because BioGaia will not publish its interim report until
10 May, BioGaia is also publishing IBT’s results for the first quarter today.
Latest press releases from BioGaia
2016-04-25 BioGaia ́s oral health probiotics to be launched in Hong Kong
2016-04-06 Notice to attend the Annual General Meeting of BioGaia AB (publ)
2016-03-18 Extraordinary General Meeting of BioGaia AB
BioGaia has published this information in accordance with the Swedish Securities
Act. The information was issued for publication on 27 April 2016 08:15 am CET.
For additional information contact:
Axel Sjöblad, Managing Director, BioGaia AB, telephone 46 8-555 293 00
or Margareta Hagman, Executive Vice President, BioGaia AB, telephone 46 8-555
293 00
BioGaia is a healthcare company that develops, markets and sells probiotic
products with documented health benefits. The products are primarily based on
the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health
-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted
on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com
